title: [Predictive value of intraepithelial (CD3) T-lymphocyte infiltration in resected colorectal cancer].
abstract: BACKGROUND
  Colorectal cancer (CRC) can induce an anti-tumoral immune response mediated by T-lymphocytes, which express CD3.
  
  
  OBJECTIVE
  To analyze the prognostic value of tissue expression of intraepithelial CD3 (CD3I) both overall and in the early tumoral stages.
  
  
  METHODS
  We revised 251 patients with resected CRC and favorable clinical course. CD3I expression was analyzed by immunohistochemistry. Multivariate analysis was used to analyze the variables independently associated with survival. We analyzed CD3I(+) expression in relation to survival and tumoral progression, both overall and in patients with pTNM(I-II) stage tumors. The sensitivity, specificity, positive and negative predictive values and diagnostic accuracy of CD3I expression were analyzed.
  
  
  RESULTS
  A total of 25.9% of patients with CRC were CD3I(+). After a mean follow-up of 74 months, CD3I(+) expression showed a favorable prognostic value for survival in the multivariate analysis (p=0.045). Survival curves and absence of tumoral progression were more favorable in CD3I(+) cases, both overall (p=0.009 and p=0.004, respectively), and in stages I-II (p=0.029 and p=0.015). The specificity and positive predictive value of CD3I(+) were as follows: Survival: overall: specificity =0.89; positive predictive value =0.91. Stage (I-II): specificity =0.94; positive predictive value =0.98. Absence of tumoral progression: overall: specificity=0.89; positive predictive value =0.88. Stage (I-II): specificity =0.92; positive predictive value =0.96.
  
  
  CONCLUSIONS
  CD3I expression has an favorable independent prognostic value, with statistically significantly higher percentages of survival and absence of tumoral progression. This more favorable outcome is maintained in the less advanced stages (I-II). CD3I expression shows high specificity and positive predictive value.
authors.affiliation: Servicio de Digestivo, Complejo Hospitalario de Navarra, Pamplona, España. bordafernando@yahoo.es
authors.forename: Fernando
authors.initials: F
authors.lastname: Borda
authors.forename: José María
authors.initials: JM
authors.lastname: Martínez-Peñuela
authors.forename: Ana
authors.initials: A
authors.lastname: Borda
authors.forename: Miguel
authors.initials: M
authors.lastname: Muñoz-Navas
authors.forename: Javier
authors.initials: J
authors.lastname: Jiménez
authors.forename: Cristina
authors.initials: C
authors.lastname: Carretero
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017252:CD3 Complex / Q000032:analysis; D002277:Carcinoma / Q000276:immunology / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D015179:Colorectal Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D018450:Disease Progression; D004848:Epithelium / Q000276:immunology / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D053208:Kaplan-Meier Estimate; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000473:pathology*
chemical_list: D017252:CD3 Complex